Stephen Saad, a South African billionaire and pharmaceutical mogul, has increased his investment in Aspen Pharmacare to more than $620 million due to a significant increase in the company’s share price on the Johannesburg Stock Exchange.
The market value of Saad’s share in Aspen has risen by R997.3 million ($52.4 million) to R11.87 billion ($623.64 million). This increase is linked to the growing interest of local bourse investors in the Durban-based pharmaceutical conglomerate.
As a global leader in the specialized and branded pharmaceutical industries for over two decades, Aspen Pharmacare has secured its position in the sector, helping to enhance healthcare in over 115 countries.
The recent increase in Aspen shares, which is 9.18% since February 12, has helped shareholders tremendously, with Saad being a big gainer. The company’s shares increased from R190.17 ($9.99) to R207.62 ($10.91), cementing Stephen Saad’s status as one of the wealthiest investors on the JSE.
Saad, who started the company in 1997, now owns a 12.5% ownership, or 57,151,972 ordinary shares in the branded pharmaceutical holding company. With a shareholding worth more than $620 million, he is one of Africa’s wealthiest men.
The recent single-digit percentage gain in Aspen’s share price has increased the market value of Saad’s interest from R10.87 billion ($571.2 million) on Feb. 12 to R11.87 billion ($623.6 million) as of the time of writing.
This increase in Saad’s stake reinforces his position as a significant role in South Africa’s commercial environment, putting him among the top investors on the JSE. This demonstrates his strong leadership and managerial abilities, strengthening his position in the commercial world.